In final data from the Phase III ENLIVEN study, Turalio (pexidartinib) demonstrated durable tumor responses and a consistent ...

Ovarian Cancer Drugs Market grows as FDA, EMA fast-track advanced-stage therapies, boosting global approvals and innovation. Anurag Tiwari Orion Market Research Pvt Ltd + +91 91798 28694 email us here ...

The Campania Oncology Network was represented by the scientific director of Pascale, Alfredo Budillon, at the Midsummer ...

Collection of ethnicity data in clinical research has been poor historically, but is essential to ensure that interventions are effective and safe across diverse populations. These data are needed to ...

Daiichi Sankyo signs a $300m deal with Alteogen to develop a subcutaneous version of anti-HER2 cancer drug Enhertu.

AstraZeneca AZN is one of the leading drugmakers in the oncology space. Oncology sales (comprising around 41% of AstraZeneca‘s total revenues) rose 13% in the first quarter of 2025, generating $5.6 ...

Two years after AstraZeneca splashed out $1 billion upfront for rights to Daiichi Sankyo's TROP2-targeting antibody-drug conjugate DS-1062, the drug has generate promising results in advanced non ...

HER3-DXd demonstrated activity in a phase 3 trial of patients with previously treated, EGFR-mutant NSCLC, but the BLA for HER3-DXd has been withdrawn.

In a new consensus statement, the European Society of Cardiology has declared vaccinations for common infections to be a ...

The trove of more than 200 letters is part of a pledge of transparency from the agency, with the intention to increase public ...

TIGIT-targeting therapies have largely disappointed in recent months, with failed studies, terminated partnerships and ...